TSHA

Taysha Gene Therapies, Inc. (TSHA) ESG Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Environmental

No material environmental disclosure or sustainability-specific news was provided this month.

The company remains in a cash-intensive development phase, with negative free cash flow and high R&D spend (22.3% of revenue), which limits near-term environmental score improvement.

Social

No material social disclosure or workforce/customer news was provided this month.

High R&D intensity and a strong cash position support continued investment in talent and operations, but there is no fresh evidence of a step-change in social performance.

Governance

No material governance news, litigation, or capital-structure changes were provided this month.

Balance-sheet liquidity remains strong with a current ratio of 17.8x and cash ratio of 17.5x, but profitability and cash-flow metrics remain deeply negative.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Taysha Gene Therapies, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →